Virbac develops and sells veterinary medicines, vaccines, and pet-care products for companion animals and livestock. The French group focuses exclusively on animal health, with a broad portfolio spanning antiparasitics, antibiotics, dermatology, and nutrition. It reaches veterinarians and farmers through specialty distribution in many countries, positioning itself as a pure-play alternative to diversified pharma giants.
| Year | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| 2022 | 1,216.2 | — | 121.9 | — |
| 2023 | 1,246.9 | 2.5% | 121.3 | -0.5% |
| 2024 | 1,397.4 | 12.1% | 145.3 | 19.8% |
| 2025 | 1,464.7 | 4.8% | 150.9 | 3.9% |
All markets — KeepWinning global stock screener
Other companies on Euronext Paris: Lagardere SA (MMB), Alten S.A. (ATE), Interparfums SA (ITP), Verallia Société Anonyme (VRLA), Société Industrielle et Financière de l'Artois Société anonyme (ARTO), COFACE SA (COFA)